Gene Therapy for Intervertebral Disk Degeneration

Orthopedic Clinics of North America

Volumn 42, Issue 4, 2011, Pages 563-574

  Woods, Barrett I ^a,b   Vo, Nam ^a,b   Sowa, Gwendolyn ^a,b   Kang, James D ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Intervertebral disk degeneration; Treatment

Indexed keywords

ADENOVIRUS VECTOR; AGGRECAN; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 2; LIM MINERALIZATION PROTEIN 1; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PROTEOGLYCAN; REGULATOR PROTEIN; SMALL INTERFERING RNA; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

CARBOHYDRATE SYNTHESIS; CELL POPULATION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DNA VECTOR; DRUG INTERACTION; DRUG MECHANISM; EX VIVO GENE TRANSFER; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IN VIVO GENE TRANSFER; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DEGENERATION; MARKER GENE; MOLECULAR CLONING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TRANSGENE; TREATMENT INDICATION; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTERVERTEBRAL DISC DEGENERATION; PROGNOSIS; RABBITS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80053198649     PISSN: 00305898     EISSN: 15581373     Source Type: Journal    
DOI: 10.1016/j.ocl.2011.07.002     Document Type: Review

References (45)

1. Luo X., Pietrobon R., Sun S.X., et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine (Phila Pa 1976) 2004, 29:79-86.
2. Buijs P.C., Lambeek L.C., Koppenrade V., et al. Can workers with chronic back pain shift from pain elimination to function restore at work? qualitative evaluation of an innovative work related multidisciplinary programme. J Back Musculoskelet Rehabil 2009, 22:65-73.
3. Bono C.M., Lee C.K. Critical analysis of trends in fusion for degenerative disc disease over the past 20 years: influence of technique on fusion rate and clinical outcome. Spine (Phila Pa 1976) 2004, 29:455-463. [discussion: Z5].
4. Hwang S.L., Hwang Y.F., Lieu A.S., et al. Outcome analyses of interbody titanium cage fusion used in the anterior discectomy for cervical degenerative disc disease. J Spinal Disord Tech 2005, 18:326-331.
5. Karasek M., Bogduk N. Twelve-month follow-up of a controlled trial of intradiscal thermal anuloplasty for back pain due to internal disc disruption. Spine (Phila Pa 1976) 2000, 25:2601-2607.
6. Hubert M.G., Vadala G., Sowa G., et al. Gene therapy for the treatment of degenerative disk disease. J Am Acad Orthop Surg 2008, 16:312-319.
7. Kelsey J.L., Githens P.B., Walter S.D., et al. An epidemiological study of acute prolapsed cervical intervertebral disc. J Bone Joint Surg Am 1984, 66:907-914.
8. Noponen-Hietala N., Kyllonen E., Mannikko M., et al. Sequence variations in the collagen IX and XI genes are associated with degenerative lumbar spinal stenosis. Ann Rheum Dis 2003, 62:1208-1214.
9. Pluijm S.M., van Essen H.W., Bravenboer N., et al. Collagen type I alpha1 Sp1 polymorphism, osteoporosis, and intervertebral disc degeneration in older men and women. Ann Rheum Dis 2004, 63:71-77.
10. Sambrook P.N., MacGregor A.J., Spector T.D. Genetic influences on cervical and lumbar disc degeneration: a magnetic resonance imaging study in twins. Arthritis Rheum 1999, 42:366-372.
11. Colombini A., Lombardi G., Corsi M.M., et al. Pathophysiology of the human intervertebral disc. Int J Biochem Cell Biol 2008, 40:837-842.
12. Buckwalter J.A. Aging and degeneration of the human intervertebral disc. Spine (Phila Pa 1976) 1995, 20:1307-1314.
13. Urban J.P., Roberts S. Degeneration of the intervertebral disc. Arthritis Res Ther 2003, 5:120-130.
14. Urban J.P., McMullin J.F. Swelling pressure of the inervertebral disc: influence of proteoglycan and collagen contents. Biorheology 1985, 22:145-157.
15. Roberts S., Evans H., Trivedi J., et al. Histology and pathology of the human intervertebral disc. J Bone Joint Surg Am 2006, 88(Suppl 2):10-14.
16. Butler D., Trafimow J.H., Andersson G.B., et al. Discs degenerate before facets. Spine (Phila Pa 1976) 1990, 15:111-113.
17. Kang J.D., Georgescu H.I., McIntyre-Larkin L., et al. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine (Phila Pa 1976) 1996, 21:271-277.
18. Kang J.D., Stefanovic-Racic M., McIntyre L.A., et al. Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Contributions of nitric oxide, interleukins, prostaglandin E2, and matrix metalloproteinases. Spine (Phila Pa 1976) 1997, 22:1065-1073.
19. Le Maitre C.L., Freemont A.J., Hoyland J.A. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol 2004, 204:47-54.
20. Le Maitre C.L., Freemont A.J., Hoyland J.A. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther 2005, 7:R732-R745.
21. Nishida K., Doita M., Takada T., et al. Sustained transgene expression in intervertebral disc cells in vivo mediated by microbubble-enhanced ultrasound gene therapy. Spine (Phila Pa 1976) 2006, 31:1415-1419.
22. Robbins P.D., Ghivizzani S.C. Viral vectors for gene therapy. Pharmacol Ther 1998, 80:35-47.
23. Tripathy S.K., Black H.B., Goldwasser E., et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996, 2:545-550.
24. Yang Y., Nunes F.A., Berencsi K., et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994, 91:4407-4411.
25. Evans C.H., Robbins P.D. Possible orthopaedic applications of gene therapy. J Bone Joint Surg Am 1995, 77:1103-1114.
26. Thompson J.P., Oegema T.R., Bradford D.S. Stimulation of mature canine intervertebral disc by growth factors. Spine (Phila Pa 1976) 1991, 16:253-260.
27. Osada R., Ohshima H., Ishihara H., et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res 1996, 14:690-699.
28. Takegami K., Thonar E.J., An H.S., et al. Osteogenic protein-1 enhances matrix replenishment by intervertebral disc cells previously exposed to interleukin-1. Spine (Phila Pa 1976) 2002, 27:1318-1325.
29. Li J., Yoon S.T., Hutton W.C. Effect of bone morphogenetic protein-2 (BMP-2) on matrix production, other BMPs, and BMP receptors in rat intervertebral disc cells. J Spinal Disord Tech 2004, 17:423-428.
30. Tim Yoon S., Su Kim K., Li J., et al. The effect of bone morphogenetic protein-2 on rat intervertebral disc cells in vitro. Spine (Phila Pa 1976) 2003, 28:1773-1780.
31. Gruber H.E., Norton H.J., Hanley E.N. Anti-apoptotic effects of IGF-1 and PDGF on human intervertebral disc cells in vitro. Spine (Phila Pa 1976) 2000, 25:2153-2157.
32. Wehling P., Schulitz K.P., Robbins P.D., et al. Transfer of genes to chondrocytic cells of the lumbar spine. Proposal for a treatment strategy of spinal disorders by local gene therapy. Spine (Phila Pa 1976) 1997, 22:1092-1097.
33. Nishida K., Kang J.D., Suh J.K., et al. Adenovirus-mediated gene transfer to nucleus pulposus cells. Implications for the treatment of intervertebral disc degeneration. Spine (Phila Pa 1976) 1998, 23:2437-2442. [discussion: 2443].
34. Sobajima S., Kim J.S., Gilbertson L.G., et al. Gene therapy for degenerative disc disease. Gene Ther 2004, 11:390-401.
35. Takada T., Nishida K., Doita M., et al. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine (Phila Pa 1976) 2002, 27:1526-1530.
36. Nishida K., Kang J.D., Gilbertson L.G., et al. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Phila Pa 1976) 1999, 24:2419-2425.
37. Moon S.H., Nishida K., Gilbertson L.G., et al. Biologic response of human intervertebral disc cells to gene therapy cocktail. Spine (Phila Pa 1976) 2008, 33:1850-1855.
38. Wallach C.J., Sobajima S., Watanabe Y., et al. Gene transfer of the catabolic inhibitor TIMP-1 increases measured proteoglycans in cells from degenerated human intervertebral discs. Spine (Phila Pa 1976) 2003, 28:2331-2337.
39. Yoon S.T., Park J.S., Kim K.S., et al. ISSLS prize winner: LMP-1 upregulates intervertebral disc cell production of proteoglycans and BMPs in vitro and in vivo. Spine (Phila Pa 1976) 2004, 29:2603-2611.
40. Paul R., Haydon R.C., Cheng H., et al. Potential use of Sox9 gene therapy for intervertebral degenerative disc disease. Spine (Phila Pa 1976) 2003, 28:755-763.
41. Kakutani K., Nishida K., Uno K., et al. Prolonged down regulation of specific gene expression in nucleus pulposus cell mediated by RNA interference in vitro. J Orthop Res 2006, 24:1271-1278.
42. Wallach C.J., Kim J.S., Sobajima S., et al. Safety assessment of intradiscal gene transfer: a pilot study. Spine J 2006, 6:107-112.
43. Chtarto A., Bender H.U., Hanemann C.O., et al. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther 2003, 10:84-94.
44. Ueblacker P., Wagner B., Kruger A., et al. Inducible nonviral gene expression in the treatment of osteochondral defects. Osteoarthr Cartil 2004, 12:711-719.
45. Lattermann C., Oxner W.M., Xiao X., et al. The adeno associated viral vector as a strategy for intradiscal gene transfer in immune competent and pre-exposed rabbits. Spine (Phila Pa 1976) 2005, 30:497-504.